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this study was aimed to compare the surgical outcomes between conventional laparoscopic distal 
gastrectomy (cLDG) and integrated robotic distal gastrectomy (iRDG) which used both Single-Site 
platform and fluorescence image-guided surgery technique simultaneously. Retrospective data of 
56 patients who underwent IRDG and 152 patients who underwent CLDG were analyzed. Propensity 
score matching analysis was performed to control selection bias using age, sex, American Society of 
Anesthesiologists score, and body mass index. Fifty-one patients were selected for each group. Surgical 
success was defined as the absence of open conversion, readmission, major complications, positive 
resection margin, and inadequate lymph node retrieval (<16). Patients characteristics and surgical 
outcomes of IRDG group were comparable to those of CLDG group, except longer operation time (159.5 
vs. 131.7 min; P < 0.001), less blood loss (30.7 vs. 73.3 mL; P = 0.004), higher number of retrieved 
lymph nodes (LNs) (50.4 vs. 41.9 LNs; P = 0.025), and lower readmission rate (2.0 vs. 15.7%; P = 0.031). 
Surgical success rate was higher in IRDG group compared to CLDG group (98.0 vs. 82.4%; P = 0.008). 
In conclusion, this study found that IRDG provides the benefits of higher number of retrieved LNs, less 
blood loss, and lower readmission rate compared with CLDG in patients with early gastric cancer.
Laparoscopic distal gastrectomy has been widely used to treat early gastric cancer (EGC)1. This procedure pro-
vides advantages of minimally invasive surgery (MIS) over open gastrectomy with decreasing postoperative pain, 
pulmonary complications, hospital stay, and improving quality of life2–4. In recent years, robotic surgery has been 
used as an alternative to laparoscopy for gastrectom y5. However, studies have shown that surgical outcomes of 
robotic gastrectomy were comparable to those of laparoscopic gastrectomy6–9.
Conventionally, robotic surgery provides potential benefits over laparoscopic surgery, such as EndoWrist 
instruments, and an ergonomic console system. In addition to these conventional benefits of robotic surgery, 
recent robotic surgical systems are equipped with Single-Site platform (Intuitive Surgical, Sunnyvale, CA, USA) 
and fluorescence imaging technology (Firefly). The Single-Site platform allows to reduce the number of ports 
during robotic surgery for abdominal organ10,11. Fluorescence image-guided surgery shows the possibility of 
adequate lymphadenectomy through visualization of lymphatic channel and lymph node (LN)12. Our institution 
reported the surgical outcomes of robotic gastrectomy using Single-Site platform13 and Firefly technology14, how-
ever, these technologies have never been applied simultaneously in an integrated procedure.
It was hypothesized that a robotic system integrated with both Single-Site platform and fluorescence imaging 
technology improve surgical outcomes. Single-Site platform can reduce the number of trocars since one video 
scope, two robotic arms, and one assistant port are introduced into the abdominal cavity via a single port. This 
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may minimize surgical trauma associated with multiple trocar insertions. Fluorescence imaging can help iden-
tify lymphatics during operation. Visualization of lymphatics increase the number of retrieved LNs, which is 
a surrogate marker for oncological safety, and reduce injury to adjacent pancreatic tissue and vessels during 
lymphadenectomy.
The aim of study was to compare the short-term surgical outcomes between integrated robotic distal gastrec-
tomy (IRDG) and conventional laparoscopic distal gastrectomy (CLDG). A collective terminology of surgical 
success was defined to assess the quality of surgery.
Methods
Study design and patients. A robotic gastric surgery procedure which uses both Single-Site platform and 
fluorescence image-guided technology was started at our institution in July 2015. Since then, based on patient 
preference, both laparoscopic and robotic gastrectomy procedures have been performed. Patients were offered 
the choice to undergo robotic or laparoscopic gastrectomy. Each patient was given a detailed explanation for 
each type of surgery and chose the type of surgery before operation. Written informed consent for surgery was 
obtained from all patients. Between July 2015 and July 2017, 277 consecutive patients underwent IRDG (n = 65) 
or CLDG (n = 212) gastrectomy. All cases of gastrectomy were performed by a single surgeon (KHI). Patients 
who underwent total gastrectomy (n = 18), proximal gastrectomy (n = 28), completion total gastrectomy (n = 1), 
and combined resection (n = 22) were excluded to compare perioperative outcomes of distal gastrectomy. In total, 
208 patients were included in our analysis. Among these patients, 56 underwent IRDG while 152 underwent 
CLDG. The Institutional Review Board of Severance Hospital approved this study and waived the need for written 
informed consent from the participants (IRB No: 4-2017-0810).
Integrated robotic distal gastrectomy. In this study, integrated robotic surgery was defined as using of 
fluorescence imaging technology and Single-Site platform in robotic surgery.
Endoscopic indocyanine green injection. Indocyanine green (ICG, Dongindang Pharmaceutical Co., Siheung, 
Korea) was used as a near-infrared (NIR) fluorescent contrast agent for intraoperative fluorescence imaging. 
ICG solution was endoscopically injected into submucosal layer at four sites (0.6 mL at each site, for a total ICG 
amount of 3 mg) around primary tumor on the day before surgery (Fig. 1), and metal clip was placed for tumor 
localization.
Single-Site platform. The da Vinci Si or Xi Systems (Intuitive Surgical, Sunnyvale, CA, USA) were used to inte-
grate Single-Site and Firefly technologies. Reduced-port robotic gastrectomy using Single-Site platform for Si 
system has been described previously13. In this paper, surgical procedures are described for Xi systems. Figure 2A 
illustrates schematic assignment of robot arms for Single-Site. A 12-mm port (XCEL, Ethicon Endo-surgery, 
Cincinnati, OH, USA) was inserted along the right flank, and an 8-mm straight cannula (470,002, Intuitive 
Surgical) was inserted in a port-in-port manner docked on the first robotic arm for equipping ultrasonic shears 
(Harmonic ACE Curved Shears, 480,275, Intuitive Surgical). Single-Site port positioned at umbilical site had 
four lumens for instruments. Needle Driver (EndoWrist Needle Driver, 478,115, Intuitive Surgical) was inserted 
through a 5-mm curved cannula (478,072, Intuitive Surgical) docked on the second robotic arm. A 10-mm acces-
sory port (10-mm Accessory Cannula, 428,076, Intuitive Surgical) was inserted to Single-Site port for assistance. 
The da Vinci Xi 30° Endoscope (470,027, Intuitive Surgical) was inserted through an 8-mm camera cannula 
(478,063, Intuitive Surgical) docked on the third robotic arm. Cadiere Forceps (EndoWrist Grasper, 478,055, 
Intuitive Surgical) was inserted through a 5.0-mm curved cannula (478,071, Intuitive Surgical) docked on the 
fourth robotic arm. Figure 2B shows the external view of robot arms installed for operation.
Firefly technology. The Firefly system was used for fluorescence image-guided lymphadenectomy (Fig. 3). 
Fluorescence image provides real-time and image-guided identification of lymphatic drainage using NIR tech-
nology. Fluorescence imaging improves visual acuity, precision, and control of lymphadenectomy by providing 
surgeons with a view of lymphatic drainage that is superior to that of the naked eye. D1 imlymphadenectomy 
(dissection of group D1 and number 8a, 9 LNs) was performed according to the Korean and Japanese gastric 
cancer treatment guidelines15,16.
Surgical wound closure after IRDG. A closed suction drain was inserted through a 12-mm port site in the right 
flank. After drain placement, the umbilical wound for Single-Site was closed in layers as follows. First, the peri-
toneum and fascia layer were closed interruptedly with Polyglactin 910 (VICRYL Plus) 1–0 sutures. Next, for the 
umbilical wound, subcuticular sutures of both sides of the skin were performed using Polyglactin 910 (VICRYL 
Plus) 4–0 sutures. Figure 4 photograph shows the umbilical wound and inserted drain after IRDG.
Conventional laparoscopic distal gastrectomy. The CLDG was performed in standardized surgical 
procedures as previously described17,18. The extent of lymphadenectomy was D1+ as done in IRDG. The recon-
struction type was determined according to the location of tumor. Reconstruction method was performed by 
intracorporeal anastomosis.
Postoperative management and complication assessment. Both groups received the same post-
operative management. Patient-controlled analgesia was used for postoperative pain control until postoperative 
day 2. Oral analgesics were initiated on postoperative day 3. Using the visual analog scale (VAS), postoperative 
pain was scored from 0 to 10. Pain score was recorded 30 minutes postoperatively in the post anesthesia care unit 
(PACU) and recorded at 3, 6, 12, 24, and 48 hours postoperatively in the ward. Sips of water on postoperative day 
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2 were followed by clear liquid diet on postoperative day 3. Soft diet was allowed on the evening of postoperative 
day 3. The Clavien-Dindo classification was used to evaluate 30-day postoperative morbidity and mortality19.
Surgical success. In previous studies, it was considered a surgical failure if the following events were 
observed during the perioperative period20,21. (1) conversion to laparoscopic or open surgery for any reasons, 
(2) harvesting an inadequate number of LNs (defined as <116), (3) positive resection margin, (4) 30-day major 
postoperative complications defined as grade III or higher according to the Clavien-Dindo classification19, or (5) 
outpatient complications leading to readmission. Any unplanned visit to the emergency department within 90 
days after index hospitalization was also regarded as readmission. A low occurrence of these events was consid-
ered a prerequisite for successful surgery, ensuring surgical and oncological safety.
Propensity score matching. Propensity score matching (PSM) analysis was performed to reduce poten-
tial selection bias with the following covariates: age, sex, American Society of Anesthesiologists (ASA) score, 
and body mass index (BMI). Individual propensity scores were calculated using a logistic regression model, and 
patients between the two groups were matched using the nearest-neighbor matching algorithm (ratio =r1:1 with-
out replacement) with a caliper width of 0.1 standard deviation of the propensity score22. After PSM, 102 patients 
(51 patients each for IRDG and CLDG groups) were analyzed to compare surgical outcomes.
Statistical analysis. Data were analyzed using IBM SPSS version 23.0 (SPSS Inc., Chicago, IL, USA). 
Continuous variables were analyzed with paired t test. Chi square test or Fisher’s exact test were performed for 
categorical variables. Statistical significance was defined as P-value <0.05.
Results
Patient demographics. Table 1 lists the clinicopathological characteristics of IRDG and CLDG groups 
before and after PSM. Before PSM, IRDG group was younger than CLDG group (56.4 vs. 61.8 years; P = 0.020). 
After PSM, matched group showed no significant difference in baseline characteristics.
Figure 1. Endoscopic indocyanine green injection. (A) Submucosal injection of indocyanine green at the day 
before surgery (B) Post-injection view.
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Surgical outcomes. As shown in Table 2, the mean operative time was longer in IRDG group than in CLDG 
group (before matching: 157.8 vs. 125.7 min; P <0.001, after matching: 159.5 vs. 131.7 min; P <0.001). IRDG 
group was associated with a significantly less estimated blood loss (before matching: 32.4 vs. 68.2 mL; P <0.001, 
after matching: 30.7 vs. 73.3 mL; P = 0.004) and higher mean number of retrieved LNs (before matching: 50.6 vs. 
44.6 LNs; P = 0.030, after matching: 50.4 vs. 41.9 LNs; P = 0.025) than CLDG group.
Changes in serum levels of C-reactive protein (CRP), amylase, and lipase were examined on postoperative 
days 0, 1, 3, and postoperative weeks 4. Serum levels of CRP were higher in IRDG group than in CLDG group on 
postoperative day 1 (before matching: 38.3 vs. 30.1 mg/L; P = 0.017, after matching: 39.0 vs. 27.2 mg/L; P = 0.002). 
There were no differences in serum levels of amylase and lipase between the two groups. The amount of drain-
age was significantly less in IRDG group than in CLDG group on postoperative day 0 (before matching: 83.0 
Figure 2. Reduced-port robotic gastrectomy. (A) Schematic illustration of reduced-port robotic distal 
gastrectomy using da Vinci Xi. (B) External view after installation Figure 2A is produced by MID (Medical 
Illustration & Design), a part of the Medical Research Support Services of Yonsei University College of 
Medicine, which is available under the Creative Commons Attribution 4.0 International License. (https://
creativecommons.org/licenses/by/4.0/). DOF, degrees of freedom.
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vs. 113.4 mL; P = 0.002, after matching: 87.3 vs. 110.1 mL; P = 0.045). Visual analog scales at each postoperative 
period were not statistically different between the two groups.
The readmission rate was significantly lower in IRDG group than in CLDG group (after matching: 98.0 vs. 
84.3%; P = 0.031). The incidence of in-hospital and out-patient complications were similar between the two 
groups. There was no operative mortality either group within postoperative 30 days.
Surgical success. Surgical success rate was significantly higher in IRDG group compared to CLDG group, 
regardless of matching (Table 3, before matching: 98.2 vs. 89.5%; P = 0.046, after matching: 98.0 vs. 82.4%; 
P = 0.008). In IRDG group, surgical failure occurred in only one patient, who was readmitted due to complication 
identified in outpatient clinic. Except for this one instance, there was no surgical failure in IRDG group regarding 
major complications, inadequate retrieved LNs (<16), conversion operation, or positive margin.
Discussion
To the best of our knowledge, this study is the first clinical outcome report of robotic surgery integrating 
Single-Site platform and Firefly technology for reduced-port surgery and fluorescence image-guided lym-
phadenectomy, respectively. The surgical outcomes following IRDG were notable to those of CLDG in terms 
of retrieved LNs, estimated blood loss, and readmission, but unfavorable in operation time. Other parameters, 
including complications, bowel recovery, drainage characteristics, and pain score, did not differ significantly 
Figure 3. Fluorescence guided lymph node dissection. (A) Lymph nodes in white light. (B) fluorescence image 
visualizing lymph node.
Figure 4. Surgical wound. A drain is inserted via right trocar site. Umbilicus was closed with subcuticular 
suture.
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between the two groups. However, regarding the proportion of patients with surgical success, IRDG showed a 
significantly higher success rate than CLDG.
The advantages of IRDG found in this study were higher number of retrieved LNs and less blood loss com-
pared to CLDG. The number of retrieved LNs is considered a surrogate marker for long-term outcomes and 
intraoperative bleeding during gastrectomy is known to be related to the risk of tumor recurrence23–25. Therefore, 
the large number of retrieved LNs and low bleeding during surgery suggest that IRDG might be safely used in 
gastric cancer surgery in terms of oncological aspect. Intraoperative bleeding is also associated with the forma-
tion of peritoneal adhesion, which is related to equilibrium disturbance between coagulation and fibrinolysis26,27. 
Even in the absence of previous serosal injury, intraoperative bleeding causes postoperative peritoneal adhesion, 
a major cause of postoperative complications. However, despite less intraoperative bleeding in robotic gastrec-
tomy, previous studies have shown similar complication rates between conventional robotic and laparoscopic 
gastrectomy28,29. In this study, grade II or higher complication rates were lower in the IRDG group, while it was 
not statistically significant. Therefore, large-scale prospective study should be performed to confirm that reducing 
intraoperative blood loss in IRDG may improve postoperative morbidity.
Shortcomings of IRDG found in this study were relatively longer operation time and CRP elevation. Because 
longer operation time is a common drawback of robot surgery30,31, operation time of this study is acceptable. 
However, CRP level was higher on postoperative day 1 compared to CLDG group. It implies that less invasive 
surgery through less port site is not effective enough to compensate for longer operation time yet. This study 
compared the initial experience of IRDG to that of fully optimized CLDG. The learning effect and optimization 
of IRDG procedures might improve operation time and associated CRP levels.
Surgical success defined in this study was adapted to compare surgical quality following procedures of robot 
and laparoscopy20,21. Since robotic and laparoscopic surgery belong to the same area of minimally invasive sur-
gery, providing surgical benefits that significantly surpass the laparoscopic surgery is a big hurdle for robotic 
surgery. Thus, collective terminology of surgical success was used to combine the rare unfavorable events in 
different domains into single parameter. Individual events related with surgical quality, such as complications and 
inadequate LN retrieval may be insufficient to show significant differences since the number of individual events 
Variable
Entire cohort Matched cohort
IRDG 
(n = 56)
CLDG 
(n = 152) P
IRDG 
(n = 51)
CLDG 
(n = 51) P
Age, years 56.4 ± 11.5 61.8 ± 10.7 0.020 58.1 ± 10.8 58.0 ± 11.1 0.964
Sex 0.234 1.000
  Male 28 (50.0) 90 (59.2) 27 (52.9) 27 (52.9)
  Female 28 (50.0) 62 (40.8) 24 (47.1) 24 (47.1)
BMI, kg/m2 23.9 ± 2.9 24.1 ± 3.5 0.712 24.0 ± 2.9 24.2 ± 3.7 0.761
ASA score 0.073 0.973
  1 16 (28.6) 26 (17.1) 14 (27.5) 13 (25.5)
  2 32 (57.1) 86 (56.6) 29 (56.9) 30 (58.8)
  3 8 (14.3) 40 (26.3) 8 (15.7) 8 (15.7)
Previous abdominal 
surgery 0.173 0.250
  No 40 (71.4) 122 (80.3) 36 (70.6) 41 (80.4)
  Yes 16 (28.6) 30 (19.7) 15 (29.4) 10 (19.6)
pT classification* 0.364 0.756
  pT1 50 (89.3) 136 (89.5) 46 (90.2) 48 (94.1)
  pT2 2 (3.6) 11 (7.2) 2 (3.9) 1 (2.0)
  pT3 4 (7.1) 4 (2.6) 3 (5.9) 2 (3.9)
  pT4a 0 (0) 1 (0.7) 0 (0) 0 (0)
pN classification† 0.585 0.517
  pN0 51 (91.1) 136 (89.5) 46 (90.2) 49 (96.1)
  pN1 4 (7.1) 9 (5.9) 4 (7.8) 1 (2.0)
  pN2 0 (0) 5 (3.3) 0 (0) 0 (0)
  pN3 1 (1.8) 2 (1.3) 1 (2.0) 1 (2.0)
Stage‡ 0.897 1.000
  I 52 (92.8) 139 (91.4) 48 (94.1) 48 (94.1)
  II 3 (5.4) 11 (7.2) 2 (3.9) 2 (3.9)
  III 1 (1.8) 2 (1.3) 1 (2.0) 1 (2.0)
Table 1. Clinicopathological characteristics of patients. Data are expressed as mean ± standard deviation or 
as number (percent). IRDG, integrated robotic distal gastrectomy; CLDG, conventional laparoscopic distal 
gastrectomy; BMI, body mass index; ASA, American Society of Anesthesiologists; SD, standard deviation. *pT, 
depth of invasion. †pN, lymph node involvement. ‡Stage, according to the 8th edition of the American Joint 
Committee on Cancer staging system for gastric cancer32.
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is very rare. As a combined parameter, surgical success might be effective for comparing the surgical quality of 
robotic and laparoscopic surgery in this study.
There were several limitations in this study. Due to the retrospective nature of the study, there was a risk of 
bias in the selection of the patient, even though the patients were matched to balance the two groups.In addition, 
although IRDG showed some advantages over CLDG in surgical outcomes, which factors, among robot, fluores-
cence imaging, and reduced-port, contribute to favorable surgical outcomes is still elusive. Therefore, analyzing 
Variable
Entire cohort Matched cohort
IRDG (n = 56) CLDG (n = 152) P IRDG (n = 51) CLDG (n = 51) P
Duration of operation, min 157.8 ± 41.0 125.7 ± 32.6 <0.001 159.5 ± 40.6 131.7 ± 33.9 <0.001
Extent of lymphadenectomy 1.000 1.000
  D1+ 56 (100) 152 (100) 51 (100) 51 (100)
Estimated blood loss, ml 32.4 ± 32.3 68.2 ± 91.8 <0.001 30.7 ± 28.2 73.3 ± 97.1 0.004
Retrieved lymph nodes, n 50.6 ± 19.2 44.6 ± 16.8 0.030 50.4 ± 19.1 41.9 ± 18.5 0.025
Time to first flatus, days 2.9 ± 0.5 2.9 ± 0.7 0.578 2.9 ± 0.4 2.9 ± 0.7 0.622
Length of hospital stay, days 5.0 ± 1.2 5.4 ± 1.9 0.170 5.1 ± 1.2 5.2 ± 0.9 0.781
CRP, mg/L
  POD #0 3.2 ± 9.7 1.5 ± 2.7 0.062 3.2 ± 10.1 1.2 ± 2.5 0.165
  POD #1 38.3 ± 23.0 30.1 ± 17.6 0.017 39.0 ± 21.6 27.2 ± 15.9 0.002
  POD #3 61.6 ± 38.6 73.4 ± 57.5 0.157 63.5 ± 37.7 65.0 ± 52.5 0.870
  POD #4 W 4.8 ± 12.1 5.6 ± 13.1 0.670 5.2 ± 12.6 4.0 ± 7.6 0.564
Serum Amylase, U/L
  POD #0 72.5 ± 34.2 67.0 ± 29.5 0.578 71.2 ± 31.7 68.6 ± 27.5 0.659
  POD #1 136.9 ± 180.5 136.8 ± 179.2 0.997 138.2 ± 183.7 138.7 ± 198.5 0.990
  POD #3 91.4 ± 65.2 86.7 ± 80.8 0.698 88.8 ± 60.0 86.7 ± 55.6 0.848
  POD #4 W 84.4 ± 30.8 82.4 ± 26.4 0.646 82.7 ± 30.2 84.1 ± 24.6 0.791
Serum Lipase, U/L
  POD #0 31.5 ± 11.5 30.6 ± 11.7 0.641 31.9 ± 11.8 29.4 ± 10.1 0.263
  POD #1 33.8 ± 47.0 36.4 ± 68.8 0.793 34.8 ± 49.1 28.1 ± 12.0 0.347
  POD #3 39.3 ± 28.0 36.8 ± 55.2 0.738 39.1 ± 28.6 37.9 ± 33.4 0.846
  POD #4 W 58.1 ± 35.7 53.7 ± 34.5 0.424 57.5 ± 35.8 56.6 ± 36.6 0.894
Amount of drainage, ml
  POD #0 83.0 ± 45.0 113.4 ± 67.0 0.002 87.3 ± 44.1 110.1 ± 67.0 0.045
  POD #1 98.0 ± 86.3 111.0 ± 124.0 0.472 104.3 ± 87.5 122.3 ± 158.2 0.478
  POD #2 97.5 ± 83.1 122.4 ± 140.5 0.214 94.8 ± 75.5 136.3 ± 173.1 0.119
  POD #3 87.8 ± 80.0 97.1 ± 107.2 0.555 88.4 ± 82.2 101.6 ± 124.0 0.531
Visual analog scale
  PACU 4.8 ± 1.5 4.5 ± 1.3 0.173 4.7 ± 1.4 4.4 ± 1.4 0.261
  1–3 hours 4.7 ± 1.5 4.6 ± 1.6 0.719 4.8 ± 1.6 5.0 ± 1.6 0.415
  3–6 hours 3.7 ± 1.4 3.6 ± 1.3 0.428 3.7 ± 1.3 3.5 ± 1.3 0.408
  6–12 hours 3.8 ± 1.4 3.7 ± 1.1 0.702 3.8 ± 1.4 3.7 ± 1.4 0.834
  12–24 hours 2.8 ± 1.0 2.7 ± 1.2 0.467 2.8 ± 1.1 2.6 ± 1.2 0.493
  24–48 hours 2.1 ± 0.9 1.9    ± 0.7 0.143 2.1 ± 0.9 1.9 ± 0.6 0.124
Readmission 1 (1.8) 15 (9.9) 0.075 1 (2.0) 8 (15.7) 0.031
In-hospital complication 0.387 0.467
  G1 19 (33.9) 54 (35.5) 18 (35.3) 16 (31.4)
  G2 6 (10.7) 23 (15.1) 4 (7.8) 8 (15.7)
  G3 0 (0) 3 (2.0)* 0 (0) 0 (0)
Out-patient complication 0.848 0.297
  G1 0 (0) 1 (0.7) 0 (0) 0 (0)
  G2 0 (0) 3 (2.0) 0 (0) 2 (3.9)
  G3 1 (1.8)† 5 (3.3)‡ 1 (2.0) 2 (3.9)
  G4 0 (0) 1 (0.7)§ 0 (0) 0 (0)
Table 2. Comparison of perioperative surgical outcomes. Data are expressed as mean ± standard deviation 
or as number (percent). IRDG, integrated robotic distal gastrectomy; CLDG, conventional laparoscopic distal 
gastrectomy; SD, standard deviation; POD, postoperative day; W, week; CRP, C-reactive protein; PACU, post 
anesthesia care unit. *Intra-abdominal fluid collection, afferent loop syndrome, omental infarction. †Internal 
herniation. ‡Intra-abdominal fluid collection in two patients, afferent loop syndrome, omental infarction, and 
internal herniation. §Duodenal stump leakage.
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three factors and comparing them one by one may help determine the contribution of each factor. In addition, 
there were no results for scar assessment, such as satisfaction for surgical wound or body image. Currently, there 
has been no study evaluating patient aesthetic satisfaction or quality of life after undergoing reduced-port gastrec-
tomy. Improved aesthetic result or quality of life could be potential benefits of reduced-port gastrectomy. Ongoing 
prospective study will provide more information on integrated surgery (NCT03396354).
In conclusion, IRDG using the Single-Site platform and fluorescence image-guided lymphadenectomy 
appears to provide potential benefits in surgical outcomes compared to CLDG for patients with early gastric 
cancer, relating to retrieved LNs, intraoperative bleeding, readmission, and surgical success.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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